Virtual Library
Start Your Search
A. Braun
Author of
-
+
P2.01 - Poster Session with Presenters Present (ID 461)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.01-005 - Evaluation of Circulating Tumoral Microemboli (CTM) as a Prognostic Factor in Non-Small Cell Lung Cancer (NSCLC) (ID 5391)
14:30 - 14:30 | Author(s): A. Braun
- Abstract
Background:
Much has been studied regarding the prognostic role of circulating tumor cells (CTCs) in NSCLC. CTM (defined as clusters of 3 or more cancer cells detected in peripheral blood) relationship to prognosis was previously published for small cell lung cancer (SCLC), demonstrating worst prognosis for the presence of CTM. No relevant data, however, was published for CTM in NSCLC. The objective of this study is to define the presence of CTM as a prognostic factor for survival in NSCLC and its molecular characteristics.
Methods:
It was performed a retrospective evaluation of 31 metastatic NSCLC patients positive for CTC, which were previously enrolled for CTC research in a single institution. CTC and CTM were detected by ISET (Isolation by Size of Epithelial/Trophoblastic Tumor Cells, Rarecells, France®). Included patients had metastatic disease treated in multiple lines of cytotoxic treatment. Analysis included frequencies, demographic characteristics and survival variables, including Progression Free Survival (PFS) and Overall Survival (OS), with PFS as primary endpoint. The PFS and OS were calculated based on the date of first CTC collection and first progression after collection (PFS) or death (OS). Molecular characterization was performed by immunocytochemistry for Transforming Growth Factor beta receptor (TGFßR) and Matrix Metalloproteinase 2 (MMP2).
Results:
The primary endpoint was not met. Presence of CTM did not have statistically significant influence on PFS or OS in our population. Eight patients were positive (CTM+) and 23 were negative (CTM-) for CTM. Median follow-up was 13.3 months (m). Median age was 65.5 years in CTM- and 69.6 years in CTM+ patients. Remaining demographic variables were balanced between groups. All patients had progressive disease and 9 were still alive at the time of analysis. Median PFS (mPFS) was 6.9m for CTM- and 4,5m for CTM+, with p=0.59. Median OS (mOS) was paradoxically greater in CTM+, without statistical significance (27.3m for CTM- and 31.6m for CTM+; p=0.83). Molecular characterization did not have any prognostic impact on both CTM- and CTM+ groups. No patient was positive for TGFßR and 2 CTM+ patients were positive for MMP2 (10/31 patients with isolated CTCs positive for MMP2).
Conclusion:
This retrospective analysis showed no impact on survival for the presence of CTM in NSCLC, which was opposite to findings of positive prognostic value of CTM for SCLC where CTM was a negative factor for survival. Molecular characterization also did not show differences between groups. The findings warrant further evaluation in dedicated research.
